James Warwick

James Warwick

Auto-generated profile, based on publicly available information

James Warwick

Nuclear Medicine Division, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Tuberculosis
Verified
Journal Article
Open access
ETEthan G. Thompson
Ethan G. Thompson
YDYing Du
Ying Du
SMStephanus T. Malherbe
Stephanus T. Malherbe
SSSmitha Shankar
Smitha Shankar
JBJackie Braun
Jackie Braun
MLMyungsun Lee
Myungsun Lee
Biomarkers for tuberculosis treatment outcome will assist in guiding individualized treatment and evaluation of new therapies. To identify candidate biomarkers, RNA sequencing of whole blood from a well-characterized TB treatment cohort was performed. Application of a validated transcriptional correlate of risk for TB revealed symmetry in host gene expression during progression from latent TB infection to active TB disease and resolution of disease during treatment, including return to control levels after drug therapy. The symmetry was also seen in a TB disease signature, constructed from the TB treatment cohort, that also functioned as a strong correlate of risk. Both signatures identified patients at risk of treatment failure 1-4 weeks after start of therapy. Further mining of the transcriptomes revealed an association between treatment failure and suppressed expression of mitochondrial genes before treatment initiation, leading to development of a novel baseline (pre-treatment) signature of treatment failure. These novel host responses to TB treatment were integrated into a five-gene real-time PCR-based signature that captures the clinically relevant responses to TB treatment and provides a convenient platform for stratifying patients according to their risk of treatment failure. Furthermore, this 5-gene signature is shown to correlate with the pulmonary inflammatory state (as measured by PET-CT) and can complement sputum-based Gene Xpert for patient stratification, providing a rapid and accurate alternative to current methods.

5 September 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HEHanif Esmail
Hanif Esmail
RLRachel P Lai
Rachel P Lai
MLMaia Lesosky
Maia Lesosky
Katalin A WilkinsonKatalin A Wilkinson
Katalin A Wilkinson
CGChristine M Graham
Christine M Graham
RWRobert J Wilkinson
Robert J Wilkinson
By using combined positron emission and computed tomography (PET–CT), Esmail et al. show that some patients with latent tuberculosis have signs of subclinical, active disease in the lungs and a greater likelihood of progression, suggesting a spectrum of disease rather than discrete latent and active disease states. Tuberculosis is classically divided into states of latent infection and active disease. Using combined positron emission and computed tomography in 35 asymptomatic, antiretroviral-therapy-naive, HIV-1-infected adults with latent tuberculosis, we identified ten individuals with pulmonary abnormalities suggestive of subclinical, active disease who were substantially more likely to progress to clinical disease. Our findings challenge the conventional two-state paradigm and may aid future identification of biomarkers that are predictive of progression.

1 June 2011 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
JDJurong Ding
Jurong Ding
HCHuafu Chen
Huafu Chen
CQChangjian Qiu
Changjian Qiu
WLWei Liao
Wei Liao
JWJames M. Warwick
James M. Warwick
QGQiyong Gong
Qiyong Gong

1 May 2004 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SSSoraya Seedat
Soraya Seedat
JWJames Warwick
James Warwick
BHBarend van Heerden
Barend van Heerden
CHCharmaine Hugo
Charmaine Hugo
NZNompumelelo Zungu-Dirwayi
Nompumelelo Zungu-Dirwayi
DSDan J. Stein
Dan J. Stein

14 October 2004 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
PCPaul D Carey
Paul D Carey
JWJames Warwick
James Warwick
DNDana J. H. Niehaus
Dana J. H. Niehaus
GLGeoffrey van der Linden
Geoffrey van der Linden
BHBarend B van Heerden
Barend B van Heerden
DSDan J Stein
Dan J Stein
Background: Several studies have now examined the effects of selective serotonin reuptake inhibitor (SSRI) treatment on brain function in a variety of anxiety disorders including obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), and social anxiety disorder (social phobia) (SAD). Regional changes in cerebral perfusion following SSRI treatment have been shown for all three disorders. The orbitofrontal cortex (OFC) (OCD), caudate (OCD), medial pre-frontal/cingulate (OCD, SAD, PTSD), temporal (OCD, SAD, PTSD) and, thalamic regions (OCD, SAD) are some of those implicated. Some data also suggests that higher perfusion pre-treatment in the anterior cingulate (PTSD), OFC, caudate (OCD) and antero-lateral temporal region (SAD) predicts subsequent treatment response. This paper further examines the notion of overlap in the neurocircuitry of treatment and indeed treatment response across anxiety disorders with SSRI treatment. Methods: Single photon emission computed tomography (SPECT) using Tc-99 m HMPAO to assess brain perfusion was performed on subjects with OCD, PTSD, and SAD before and after 8 weeks (SAD) and 12 weeks (OCD and PTSD) treatment with the SSRI citalopram. Statistical parametric mapping (SPM) was used to compare scans (pre- vs post-medication, and responders vs non-responders) in the combined group of subjects. Results: Citalopram treatment resulted in significant deactivation (p = 0.001) for the entire group in the superior (t = 4.78) and anterior (t = 4.04) cingulate, right thalamus (t = 4.66) and left hippocampus (t = 3.96). Deactivation (p = 0.001) within the left precentral (t = 4.26), right mid-frontal (t = 4.03), right inferior frontal (t = 3.99), left prefrontal (3.81) and right precuneus (t= 3.85) was more marked in treatment responders. No pattern of baseline activation distinguished responders from non-responders to subsequent pharmacotherapy. Conclusions: Although each of the anxiety disorders may be mediated by different neurocircuits, there is some overlap in the functional neuro-anatomy of their response to SSRI treatment. The current data are consistent with previous work demonstrating the importance of limbic circuits in this spectrum of disorders. These play a crucial role in cognitive-affective processing, are innervated by serotonergic neurons, and changes in their activity during serotonergic pharmacotherapy seem crucial.

1 July 2008 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JWJ.M. Warwick
J.M. Warwick
PCP. Carey
P. Carey
GJG.P. Jordaan
G.P. Jordaan
PDP. Dupont
P. Dupont
DSD.J. Stein
D.J. Stein